Addressing Intolerance and Resistance to BTK Inhibition Is Next Frontier in CLL Drug Development
OncLive,
The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs…
CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small…
Overview of attention for article published in Clinical Lymphoma, Myeloma & Leukemia, October 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (77th percentile)
-
High Attention Score compared to outputs of the same age and source (95th percentile)
Readers on
- mendeley
- 25 Mendeley